Catalent Pharma Solutions has announced the broadening of the scope of its OptiForm Solution Suite, an integrated offering designed to help solve bioavailability challenges for early-stage molecules from late-stage discovery to Phase I clinical trials.

The OptiForm Solution Suite service will now include more candidate-screening tools, absorption, distribution, metabolism and excretion considerations and in silico drug metabolism and pharmacokinetic modeling, additional bioavailability-enhancing tools, materials for cGLP intravenous and oral toxicological studies, and cGMP materials for first-in-human studies, according to Catalent.

The new OptiForm Solution Suite integrates tools and services sequentially to deliver relevant data and an optimized development program to support a molecule’s progress toward the clinic.

Source: Catalent Pharma Solutions